Improved treatment outcomes with (18) F-FDG PET/CT for patients with advanced head and neck squamous cell carcinoma.

Head & Neck Pub Date : 2012-09-01 Epub Date: 2011-10-29 DOI:10.1002/hed.21887

Stephan K Haerle, M B Soyka, D T Schmid, N Ahmad, G F Huber, D W Crook, T F Hany

{"title":"Improved treatment outcomes with (18) F-FDG PET/CT for patients with advanced head and neck squamous cell carcinoma.","authors":"Stephan K Haerle, M B Soyka, D T Schmid, N Ahmad, G F Huber, D W Crook, T F Hany","doi":"10.1002/hed.21887","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to assess the impact of (18) F-fluoro-2-deoxy-D-glucose ((18) F-FDG) PET/CT on survival for patients with head and neck squamous cell carcinoma correlated with a matched patient cohort.Methods: In all, disease in 58 patients was initially staged using (18) F-FDG PET/CT. A case-control analysis was done with 63 patients who disease was staged without (18) F-FDG-PET/CT.Results: Disease-specific survival (DSS) and overall survival (OS) did not show significant differences between both groups. Statistical analysis revealed no difference in DSS and OS between the 2 groups for patients treated by radiochemotherapy (p = .975 and p = .671). In the analysis of survival in patients treated by a combined approach (surgery + radiochemotherapy), a significant difference in favor of patients evaluated by (18) F-FDG PET/CT was found (p = .05 and p = .027).Conclusions: Addition of (18) F-FDG PET/CT in patients treated by surgery and conformal radiochemotherapy improves outcome. This may be due to the more comprehensive topographic orientation of the primary tumor for the surgeon.","PeriodicalId":501638,"journal":{"name":"Head & Neck","volume":" ","pages":"1205-11"},"PeriodicalIF":0.0000,"publicationDate":"2012-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hed.21887","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head & Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.21887","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/10/29 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

Background: The aim of this study was to assess the impact of (18) F-fluoro-2-deoxy-D-glucose ((18) F-FDG) PET/CT on survival for patients with head and neck squamous cell carcinoma correlated with a matched patient cohort.

Methods: In all, disease in 58 patients was initially staged using (18) F-FDG PET/CT. A case-control analysis was done with 63 patients who disease was staged without (18) F-FDG-PET/CT.

Results: Disease-specific survival (DSS) and overall survival (OS) did not show significant differences between both groups. Statistical analysis revealed no difference in DSS and OS between the 2 groups for patients treated by radiochemotherapy (p = .975 and p = .671). In the analysis of survival in patients treated by a combined approach (surgery + radiochemotherapy), a significant difference in favor of patients evaluated by (18) F-FDG PET/CT was found (p = .05 and p = .027).

Conclusions: Addition of (18) F-FDG PET/CT in patients treated by surgery and conformal radiochemotherapy improves outcome. This may be due to the more comprehensive topographic orientation of the primary tumor for the surgeon.

查看原文本刊更多论文

(18) F-FDG PET/CT对晚期头颈部鳞状细胞癌患者治疗效果的改善

背景:本研究的目的是评估(18)f -氟-2-脱氧-d -葡萄糖(18)F-FDG) PET/CT对与匹配患者队列相关的头颈部鳞状细胞癌患者生存的影响。方法:总共有58例患者使用(18)F-FDG PET/CT对疾病进行初步分期。对63例未进行F-FDG-PET/CT分期的患者进行病例对照分析。结果:两组间疾病特异性生存期(DSS)和总生存期(OS)无显著差异。经统计学分析，两组放化疗患者的DSS和OS差异无统计学意义(p = 0.975和p = 0.671)。在联合方法(手术+放化疗)治疗的患者的生存分析中，发现(18)F-FDG PET/CT评估的患者有显著差异(p = 0.05和p = 0.027)。结论:(18)F-FDG PET/CT在手术和适形放化疗患者中的应用改善了预后。这可能是由于外科医生对原发肿瘤的地形定位更为全面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Head & Neck

自引率

0.00%

发文量